Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Bleomycin + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Procarbazine + Vincristine Sulfate |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Bleomycin | Blenoxane | BLM | ||
Cyclophosphamide | Cytoxan | CPM | Chemotherapy - Alkylating 18 | Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary). |
Doxorubicin | Adriamycin | Adria|ADR|Doxorubicin hydrochloride|Hydroxydaunorubicin | Chemotherapy - Anthracycline 13 TOPO2 inhibitor 5 | Adriamycin (doxorubicin) is an anthracycline chemotherapeutic, in a non-liposomal formulation, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Doxorubicin is FDA approved for multiple cancer types (FDA.gov). |
Etoposide | Vepesid | EPEG|Eposin|VP-16|VP-16-213 | TOPO2 inhibitor 5 | Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary). |
Prednisone | Adasone | Dehydrocortisone | Adasone (prednisone) is a corticosteroid which functions as an immunosuppressant and anti-inflammatory agent and which may stimulate apoptosis in tumor cells (NCI Drug Dictionary). | |
Procarbazine | Matulane | Benzethyzin|Ibenzmethyzin|N-Methylhydrazine | Chemotherapy - Alkylating 18 | |
Vincristine Sulfate | Oncovin | 22-Oxovincaleukoblastine|vincristine | Oncovin (vincristine) binds microtubules and prevents mitotic spindle formation, resulting in cell-cycle arrest (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05675410 | Phase III | Dacarbazine + Doxorubicin + Vinblastine Bleomycin + Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine Bleomycin + Dacarbazine + Doxorubicin + Vinblastine Bleomycin + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Procarbazine + Vincristine Sulfate | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | Recruiting | USA | CAN | 1 |
NCT02661503 | Phase III | Brentuximab vedotin + Cyclophosphamide + Dacarbazine + Dexamethasone + Doxorubicin + Etoposide Bleomycin + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Procarbazine + Vincristine Sulfate | HD21 for Advanced Stages | Active, not recruiting | DEU | 0 |